Orexo enters into an alliance and license agreement for new drugs to treat respiratory diseases
Uppsala, Sweden, June 1 2010 - Orexo (OMX: ORX) has entered a research and development alliance and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV (collectively “OMJ”). The licenses granted to OMJ under the agreement include worldwide licenses to Orexo’s ongoing OX-CLI and OX-ESI programs focusing on discovering and developing innovative small-molecule treatments for asthma, chronic obstructive pulmonary disease, and other inflammatory diseases. In addition, OMJ will add a third internal program focusing on discovering and developing